Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Cardiology Care (Cert # L239200)

Teaser: This Self-Assessment Program series provides Ambulatory Care pharmacists with pertinent therapeutic updates to enhance their practice skills and improve patient outcomes.

Tag: Certifications; Ambulatory Care

ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/15/2023
Release Date: 03/15/2023
Expiration Dates: 09/15/2023
Activity Type: Application-based
CE Credits: TBD contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non-member)

Accreditation for Pharmacists
The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience
The target audience for Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Cardiology Care is board-certified and advanced level ambulatory care clinical pharmacists.

Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to TBD contact hours of continuing pharmacy education and/or recertification credit.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS.

Recertification Credit*
Board certified pharmacists are eligible to receive up to TBD contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.
LEARNING OBJECTIVES

Cardiology Care I
ACPE #: TBD

Chapter: Updates in the Management of Heart Failure
- Evaluate key recommendations and recent updates in the national guidelines in the treatment of heart failure (HF).
- Analyze drug therapies according to the revised terminology and categories of HF.
- Design practical strategies to optimize individualized guideline-directed medical therapies.

Chapter: Dyslipidemia Management Updates
- Assess low-density lipoprotein (LDL)-based treatment recommendations and targets based on common clinical dilemmas.
- Evaluate the role and place in therapy of bempedoic acid, inclisiran, and evinacumab in the treatment of dyslipidemia.
- Apply appropriate management strategies for lowering LDL in statin-intolerant patients.

Cardiology Care II
ACPE #: TBD

Chapter: DOAC Use in Special Populations
- Account for the classification of special populations for direct oral anticoagulant (DOAC) use.
- Analyze the emerging evidence for DOAC use in specific special populations.
- Apply evidence and societal guidelines to guide the use of DOACs in specific patient populations.
- Evaluate the degree of uncertainty of DOAC use in specific patient populations.

Chapter: Updates in Cardio-Oncology
- Given a patient on anticancer therapy, evaluate the patient’s risk of developing vascular toxicities, establish treatment goals, and construct a therapeutic plan.
- Devise a risk mitigation and treatment strategy for patients on anticancer therapy at risk of developing heart failure.
- Evaluate which patients on anticancer therapy are at risk of developing atrial fibrillation and design a plan for risk management and monitoring.
- For patients on anticancer therapy, assess individual risk of developing QTc prolongation and develop a plan for prevention, treatment, and surveillance.
- Assess a patient’s risk of developing myocarditis and construct a monitoring and treatment plan.
Cardiology Care III
ACPE #: TBD

Chapter: Stable Ischemic Heart Disease Management Updates
- Distinguish between drug therapy recommendations for cardiovascular (CV) risk reduction and symptomatic relief of symptoms in patients with stable ischemic heart disease (SIHD) based on current guidelines.
- Develop an evidence-based pharmacologic regimen for patients with SIHD for both CV risk reduction and symptomatic relief of symptoms.
- Analyze the optimal use of antithrombotic therapy for patients with SIHD.
- Assess the optimal use of omega-3 fatty acids in patients with SIHD and hypertriglyceridemia.
- Evaluate the impact of colchicine on CV risk reduction in patients with SIHD.

Chapter: Pharmacogenomics and Cardiovascular Disease
- Evaluate the clinical utility of pharmacogenomic testing for cardiovascular medications to guide therapeutic recommendations.
- Assess genotype results and other raw pharmacogenomic data to determine actionable prescribing utilizing pharmacogenetic guidelines, resources, and knowledgebases.
- Develop a therapeutic plan for cardiovascular health management incorporating patient specific clinical factors and pharmacogenomic test results.
- Evaluate the supporting evidence, clinical validity, and clinical utility of pharmacogenetic testing for cardiovascular medications with currently no available pharmacogenetic prescribing recommendations.

Cardiology Care IV
ACPE #: TBD

Interactive Case: Role of Colchicine in Secondary Prevention of CVD
- Discover the role of inflammation in the mediation of atherosclerotic disease progression and ultimate events.
- Assess historic strategies targeting inflammation and outcomes related to cardiovascular disease (CVD).
- Analyze the role of colchicine therapy with relation to CVD risk reduction.
- Devise a strategy for integrating colchicine into treatment plans for CV risk reduction.

Interactive Case: Peripheral Arterial Disease
- Justify the need for atherosclerotic risk reduction strategies in a patient with lower extremity peripheral artery disease (LE-PAD).
- Detect whether a patient with LE-PAD has symptoms.
- Evaluate the risk-benefit of antiplatelet therapy for a patient with asymptomatic LE-PAD.
- Design an antithrombotic treatment regimen for a patient with symptomatic LE-PAD.
- Develop an antithrombotic treatment regimen for a patient who underwent revascularization for LE-PAD.

Interactive Case: Telehealth and Self-Monitoring of Blood Pressure
- Evaluate requirements for implementing, conducting, and billing for telehealth services.
- Assess a patient’s home blood pressure monitor and technique.
- Evaluate a patient for primary, resistant, or secondary hypertension.
- Analyze a patient’s home readings, laboratory values, and medical history and recommend appropriate medication.
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
ACCP and ASHP collaborate on ambulatory care pharmacy activities.